From Broad-Spectrum Senolysis to Precision Reprogramming: Senolytika Enter Nästa Generation

A review published in Nature Aging traced the evolution of senolytic research from early first-generation compounds (navitoclax, dasatinib+quercetin combination) to next-generation approaches including precision senotherapeutics and partial reprogramming. The review noted that first-generation senolytics had broad off-target effects, and the field is moving toward more targeted approaches. For supplement consumers, the relevance is that quercetin and fisetin, which are available as supplements, are first-generation senolytics with broad mechanisms. The review suggests that the next generation may be more targeted and effective, but also that the current supplement-grade senolytics may have limitations that more precise approaches could overcome. The dasatinib+quercetin combination remains the most-studied senolytic in human trials, with the SToMP-MS and other trials ongoing.

Early first-generation senolytics including navitoclax and the dasatinib-quercetin combination are being superseded by precision approaches.